1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
Global Fusion Biopsy Market By End Use, By Route, By Region, Industry Analysis and Forecast, 2020 - 2026

Global Fusion Biopsy Market By End Use, By Route, By Region, Industry Analysis and Forecast, 2020 - 2026

  • August 2020
  • 132 pages
  • ID: 5975417
  • Format: PDF
  • KBV Research


Table of Contents

The Global Fusion Biopsy Market size is expected to reach $912.5 Million by 2026, rising at a market growth of 11.5% CAGR during the forecast period. Fusion biopsy is considered as the most reliable method of detection of prostate and breast cancer. It is difficult to visualize the entire prostrate even in the biopsy so there are many developments being done in fusion biopsy system such as trans-rectal ultra-guided prostate biopsy. The current biopsy system has less image resolution and chances biopsy needle can penetrate the tumor-free areas and it can be given negative results.

The second most common type of cancer in men is Prostate cancer. Each year more than 160,000 Americans are diagnosed with prostate cancer. For diagnosis and detection of prostate cancer, the primary diagnostic test includes Digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) as they are more affordable and accessible. Though the PSA test is largely used for the detection of benign tumors that results in pointless invasive procedures and it also costs higher healthcare. Consequently, the rising demand for a more specific and sensitive screening method in prostate cancer is likely to boost the market growth for fusion biopsy.

The survival rate in the case of prostate cancer is more as compared to other types of cancer. But, the survival rate for prostate cancer has been less reported at the metastatic stage of cancer. To prevent prostate cancer from reaching up to a metastatic stage is highly needed, and for this purpose, either active surveillance or surgical intervention with other types of medication is required. There are many risks associated with surgical intervention such as erectile dysfunction, bleeding, urinary tract infection, and urinary incontinence. Thus, patients are usually seeking active surveillance and opting for regular biopsy, which in turn, is anticipated to drive the market growth of the MR/Ultrasound biopsy system.

Based on End Use, the market is segmented into Diagnostic centers, Hospitals and Ambulatory care centers. Based on Route, the market is segmented into Transperineal and Transrectal. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Hitachi, Ltd., Baxter International, Inc. (MedCom), Esaote SpA, Eigen, KOELIS, Inc., Focal Healthcare, Inc. and UC-Care Medical Systems Ltd.

Strategies deployed in Fusion Biopsy Market

Nov-2018: Focal Healthcare received both FDA 510(k) clearance and Health Canada approval for its Fusion Bx 2.0 prostate biopsy solution. The Fusion Bx 2.0 is the second generation of Focal Healthcare’s prostate fusion biopsy device.

Sep-2016: UC-Care and AXELLA announced the Navigo and SmartBx Systems, new cutting edge vision for prostate MRI fusion biopsy. Navigo fuses previously captured prostate MRI images with live TRUS (transrectal ultrasound) images while the ultrasound transducer is inserted during the biopsy.

May-2016: Philips’ business Invivo partnered with SonaCare Medical to license Invivo’s UroNav fusion software with its Sonablate planning system. The partnership enabled clinicians to use the UroNav device to annotate and biopsy targeted prostate tissue and localizes the tissue appropriate for ablation directly with its Sonablate software.

Mar-2016: Eigen collaborated with Hitachi Medical Systems Europe. Under this collaboration, Hitachi was aimed to distribute the Artemis, Eigen’s robotic 3D targeted prostate biopsy device, through their subsidiaries’ sales network in Europe. Additionally, both companies expanded the versatility of Eigen’s Artemis and Hitachi Aloka’s suite of advanced ultrasound units, including their newest and most compact ultrasound unit yet, the Noblus.

Mar-2016: Hitachi signed an agreement with MedCom GmbH to distribute the latter company’s products through Hitachi’s subsidiaries sales network in Europe. BiopSee is the MedCom’s fusion imaging system for stereotactic, navigated, targeted prostate biopsy & therapy guidance. It is used in conjunction with Hitachi ultrasound systems. Hitachi is the sole distributor of the BiopSee products in this territory for Hitachi’s installed base and when bundled with Hitachi’s products.

Feb-2016: Focal Healthcare got 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its targeted prostate biopsy device, Fusion Bx. With the availability of Fusion Bx, clinicians can accurately take targeted biopsies directly from suspicious cancer regions within the prostate using MRI-ultrasound "fusion" technology.

Scope of the Study

Market Segmentation:

By End Use

• Diagnostic centers

• Hospitals

• Ambulatory care centers

By Route

• Transperineal

• Transrectal

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Australia

o Rest of Asia Pacific


o Brazil

o Argentina


o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Koninklijke Philips N.V.

• Hitachi, Ltd.

• Baxter International, Inc. (MedCom)

• Esaote SpA

• Eigen

• KOELIS, Inc.

• Focal Healthcare, Inc.

• UC-Care Medical Systems Ltd.

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on